arrow
I

Ira J. Goldberg

New York University
H指数:97
被引数:3.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Alveolar type 2 cell LRP1 is needed for surfactant phospholipid metabolism and pulmonary function in mice

肺泡II型细胞LRP1对于小鼠表面活性剂磷脂代谢和肺功能是必需的

2026-04-160
OAAI
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial

Zodasran降低高脂血症患者的胆固醇和甘油三酸酯: 1期篮子试验的最终报告

2026-04-070
PRE
Non-remnant triglyceride-rich lipoproteins due to lipoprotein lipase deficiency increase atherosclerosis in mice

由于脂蛋白脂肪酶缺陷导致的非残粒甘油三酯富集脂蛋白会增加小鼠的动脉粥样硬化

2026-01-030
OAAI
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial

Zodasiran,一种靶向ANGPTL3的RNAi疗法,用于治疗纯合子家族性高胆固醇血症患者(GATEWAY):一项开放标签、随机、II期临床试验

2025-12-180
PRE
Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size

脂蛋白 (a) 对有效降脂的反应变化: 载脂蛋白 (a) 同工型大小的作用

2024-12-010
PRE
FITM2 deficiency results in ER lipid accumulation, ER stress, and reduced apolipoprotein B lipidation and VLDL triglyceride secretion in vitro and in mouse liver
2024-12-010
OAAI
Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors
2024-11-291
OAAI
The immune checkpoint landscape in human atherosclerosis: influence of lipid lowering and type 2 diabetes

人类动脉粥样硬化中的免疫检查点景观:降脂治疗和2型糖尿病的影响

2024-11-120
PRE